Deepika Malik
Retina Specialist · Woodbury, NYNPI 1134530306
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $140,310 of the $221,076 with a category attached, or 63.5%. 25 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 29.2% of the total. 2025 is the largest year on record at $71,697, 4.6 times the $15,450 reported in 2019. Among retina specialist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 418 payments — averaging $528.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$65K
- Genentech USA, Inc.$58K
- Biogen$33K
- Alimera Sciences, Inc.$29K
- AbbVie$7K
- Regeneron$7K
- plus $22K from 19 others
Across 5 payments — averaging $271.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$698
- AbbVie$660
What the payments were for
- Consulting fees$48,08522%
- Speaking & faculty fees$140,31063%
- Travel & lodging$17,1598%
- Food & beverage$15,4117%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 73 | $64,657 |
| Genentech USA, Inc. | 96 | $58,434 |
| Biogen | 30 | $33,107 |
| Alimera Sciences, Inc. | 49 | $28,730 |
| AbbVie(2 entities) | 31 | $7,485 |
| Regeneron | 10 | $6,771 |
| Genentech, Inc. | 7 | $6,687 |
| Bausch & Lomb Americas Inc. | 17 | $5,525 |
| Apellis Pharmaceuticals, Inc. | 16 | $2,591 |
| Neurotech Pharmaceuticals, Inc. | 3 | $2,094 |
| Eyepoint US, Inc. | 2 | $1,615 |
| Mallinckrodt Hospital Products Inc. | 15 | $622 |
| Alcon | 9 | $539 |
| ANI Pharmaceuticals, Inc. | 19 | $508 |
| Novartis | 4 | $469 |
| Astellas Pharma US Inc | 8 | $233 |
| Harrow Eye, LLC | 9 | $226 |
| Dompe US, Inc. | 4 | $209 |
| Glaukos Corporation | 1 | $161 |
| Oyster Point Pharma, Inc. | 8 | $154 |
| Spark Therapeutics, Inc. | 1 | $125 |
| Tarsus Pharmaceuticals, Inc. | 3 | $67 |
| Biotissue Holdings Inc. | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Sight Sciences, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$221,076 in reported general payments places this provider in the 95th percentile of 99 retina specialist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 312 | $16,563 |
| CombiganBrimonidine Tartrate/Timolol | 15 | $5,276 |
| Atropine Sulfate | 133 | $4,395 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $2,941 |
| MoxifloxacinMoxifloxacin Hcl | 122 | $2,756 |
| Brimonidine Tartrate | 34 | $2,005 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 71 | $1,146 |
| Ketorolac Tromethamine | 53 | $1,139 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 12 | $656 |
| Moxifloxacin Hcl | 14 | $608 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 41 | $536 |
| Ofloxacin | 37 | $475 |
| Latanoprost | 46 | $319 |
| ErythromycinErythromycin Base | 24 | $291 |
| Acetazolamide | 12 | $170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $7,485 | $5,27615 claims |
| AlconSimbrinza | $539 | $2,94115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 99 retina specialist providers in New York.
Other retina specialist in Woodbury
- Paul HahnNanuet$238K
- Szilard KissNew York$195K
- Ferhina AliValhalla$176K
- Donald D'amicoNew York$109K
- Matthew WitmerRochester$62K
- Avnish DeobhaktaBrooklyn$46K
- Edward HallRochester$38K
- Philip NilesWilliamsville$30K
- Mark BreazzanoLiverpool$30K
- Sarwar ZahidJackson Heights$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.